Completed PHASE2 INTERVENTIONAL 5-arm NCT00415038

Efficacy of Rostafuroxin in the Treatment of Essential Hypertension

A Double Blind, Dose Range, Placebo Controlled Study of the Effects of Rostafuroxin vs Placebo in Patients With Stable, Uncomplicated, Essential Hypertension.

Sponsor: sigma-tau i.f.r. S.p.A.

Conditions Essential Hypertension

Interventions Rostafuroxin

Updated 5 times since 2017 Last updated: Jun 16, 2011 Started: Feb 28, 2005 Primary completion: Apr 30, 2007 Completion: Aug 31, 2007

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Essential Hypertension and is currently completed. sigma-tau i.f.r. S.p.A. leads this study, which shows 5 recorded versions since 2005 — indicating limited longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

sigma-tau i.f.r. S.p.A.

Data source: sigma-tau i.f.r. S.p.A.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Leuven, Belgium